CJC-1295: FDA status, evidence and safety

Status at a glance

What CJC-1295 is

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH), the signal that tells the pituitary gland to release growth hormone. WADA lists it alongside sermorelin and tesamorelin in that class. Clinics market it for body composition, recovery and sleep, usually in combination with ipamorelin (see CJC-1295 / ipamorelin).

Human evidence

FDA’s own assessment is that “available clinical data are limited” (FDA). We did not find controlled trials showing that CJC-1295 improves body composition, recovery or sleep in healthy adults, and we have not re-read the clinical literature for this update, so we cite no trial. Raising a hormone level in a blood test is not the same as showing a health benefit.

Animal and laboratory evidence

Much of the rationale for GHRH analogues comes from physiology and animal work on the growth-hormone axis. That explains the mechanism; it does not show that the marketed outcomes happen in people.

Risks

FDA states: “FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction” (FDA). A vasodilatory reaction means blood vessels widen, which can cause flushing and a drop in blood pressure. Products from research websites add unknown purity, sterility and dose.

Legal sourcing: who can supply it

With no approval, no bulks-list entry and no category, CJC-1295 has no established federal compounding route as of October 15, 2026. If a clinic offers it, ask what legal basis its pharmacy relies on, and see the peptide legality guide.

The lawful route for a prescription peptide in the United States is a licensed clinician who examines you and writes a prescription, filled by a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility that is allowed to use that substance. Websites that sell peptides “for research use only” or “not for human consumption” are not a lawful source of medicine for people. On August 24, 2026, FDA sent warning letters to five such sellers — Peptide Partners, Peak Performance Peptides, Royal Peptides, NuScience Peptides and Tex Peptides — calling their products unapproved new drugs. FDA wrote that the research-use labels did not change its view because the websites showed the products were meant for human use.

October 2026: what changed

• April 2026 — Category 2 withdrawals. FDA moved BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, injectable GHK-Cu and other peptides off its Category 2 list after the nominators withdrew them. FDA lists them as “nominated but withdrawn” (page current as of April 22, 2026). They were not moved into Category 1.
• July 23–24, 2026 — advisory committee. FDA’s Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTs-C, emideltide (DSIP), Semax and Epitalon. FDA staff proposed not adding BPC-157 or TB-500. A law-firm account reports the committee voted 8–6 (one abstention) to recommend BPC-157, KPV and TB-500 (McDermott, July 27, 2026). A vote is advice; FDA has taken no final action.
• October 14–15, 2026 — interim access policy under White House review. The OIRA review site lists “Interim Access Policy for Compounding Using Certain Peptides” from HHS/FDA (RIN 0910-ZD94, stage: Notice), received October 14, 2026 and pending review; no text has been published (reginfo.gov). Reuters reported the filing on October 15 (Reuters), and the AP, citing two people, said it would let pharmacies make some popular peptides, including BPC-157. Which peptides, on what terms and from when are not public. Our running table: peptide legal status 2026.

For CJC-1295: it left Category 2 in April but was not on the July advisory agenda, and no PCAC date has been announced. Whether the interim policy will include it is unknown. Compare the other growth-hormone peptides on sermorelin and tesamorelin.